Literature DB >> 2562385

Therapeutic potential of fish oil in the treatment of ulcerative colitis.

T B McCall1, D O'Leary, J Bloomfield, C A O'Moráin.   

Abstract

In a pilot study six patients with active ulcerative colitis and six healthy controls were given fish oil (MaxEPA) containing 3-4 g of eicosapentaenoic acid daily for a period of 12 weeks. There was a significant improvement in the patients' symptoms and histological appearance of the rectal mucosa by the end of the treatment period. There was significant fall in neutrophil chemiluminescence during treatment in patients, whereas no change was observed in the control group. Neutrophil leukotriene B4 levels fell significantly during treatment. Serum from patients receiving fish oil was significantly less chemotactic for neutrophils compared with control serum. Eicosapentaenoic acid inhibited neutrophil chemotaxis and chemiluminescence in vitro. The omega-3 fatty acids, which occur naturally in fish oils, may exert a beneficial effect by decreasing the production of inflammatory mediators.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562385     DOI: 10.1111/j.1365-2036.1989.tb00232.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.

Authors:  A B Hawthorne; T K Daneshmend; C J Hawkey; A Belluzzi; S J Everitt; G K Holmes; C Malkinson; M Z Shaheen; J E Willars
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  Serum n3 polyunsaturated fatty acids are depleted in Crohn's disease.

Authors:  F Kuroki; M Iida; T Matsumoto; K Aoyagi; K Kanamoto; M Fujishima
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

3.  Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study.

Authors:  C Romano; S Cucchiara; A Barabino; V Annese; C Sferlazzas
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

4.  The influence of membrane fluidity, TNF receptor binding, cAMP production and GTPase activity on macrophage cytokine production in rats fed a variety of fat diets.

Authors:  P S Tappia; S Ladha; D C Clark; R F Grimble
Journal:  Mol Cell Biochem       Date:  1997-01       Impact factor: 3.396

5.  n-3 fatty acids only delay early relapse of ulcerative colitis in remission.

Authors:  K Loeschke; B Ueberschaer; A Pietsch; E Gruber; K Ewe; B Wiebecke; W Heldwein; R Lorenz
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

Review 6.  Pharmacoeconomics of the therapy of diarrhoeal disease.

Authors:  K A Nathavitharana; I W Booth
Journal:  Pharmacoeconomics       Date:  1992-10       Impact factor: 4.981

Review 7.  [What is the role of nutrition in ulcerative colitis? A contribution to the current status of diet therapy in treatment of inflammatory bowel diseases].

Authors:  M Bartels; E Nagel; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1995

8.  Effects of duodenal seal oil administration in patients with inflammatory bowel disease.

Authors:  Gülen Arslan; Linn Anne Brunborg; Livar Frøyland; Johan G Brun; Merete Valen; Arnold Berstad
Journal:  Lipids       Date:  2002-10       Impact factor: 1.880

9.  Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease.

Authors:  K Hillier; R Jewell; L Dorrell; C L Smith
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

10.  Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients.

Authors:  A Belluzzi; C Brignola; M Campieri; E P Camporesi; P Gionchetti; F Rizzello; C Belloli; G De Simone; S Boschi; M Miglioli
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.